SCYX News and Press, SCYNEXIS Inc. From 09/27/23

JERSEY CITY, N.J., Sept. 27, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. is conducting a voluntary nationwide recall of 2 lots of BREXAFEMME ® (ibrexafungerp tablets) to the consumer level in the US market due to potential cross contamination with a non-antibacterial ß-lactam drug subst...

2023-09-26 19:54:24 ET Summary We downgrade Scynexis to a sell rating following the voluntary recall of antifungal pill, Brexafemme. Historical precedence suggests that manufacturing recalls can take months to resolve, and for a single-product biotech, we see further downside to t...

2023-09-25 13:00:22 ET Gainers: Vaccitech plc ADR ( VACC ) +93% . ESS Tech ( GWH ) +23% . Flora Growth Corp ( FLGC ) +22% . Avalo Therapeutics ( AVTX ) +22% . Neuraxis ( NRXS ) +19% . American Coastal Insurance Corp ( ACIC ...

2023-09-25 09:20:13 ET More on Scynexis Seeking Alpha’s Quant Rating on SCYNEXIS Historical earnings data for SCYNEXIS Financial information for SCYNEXIS For further details see: Scynexis recalling antifungal therapy on potential contamination

JERSEY CITY, N.J., Aug. 28, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that management will participate in the following investor conferen...

2023-08-16 08:33:15 ET Sacks Parente Golf ( SPGC ) -38% . Impel Pharmaceuticals ( IMPL ) -36% . SRM Entertainment ( SRM ) -22% announces pricing of its initial public offering . Coherent Corp. ( COHR ) -22% . after Q4 earning release . ...

2023-08-14 17:39:02 ET SCYNEXIS press release ( NASDAQ: SCYX ): Q2 GAAP EPS of $2.46 beats by $1.01 . Revenue of $131.5M (+9862.1% Y/Y) beats by $36.1M . Shares +2.14% AH. For further details see: SCYNEXIS GAAP EPS of $2.46 beats by $1.01, revenue...

SCYNEXIS reported the closing of an exclusive license agreement with GSK for BREXAFEMME ® (Ibrexafungerp Tablets). SCYNEXIS received an upfront payment of $90 million upon deal close. SCYNEXIS announced the achievement of the first development milestone of $25 million under the exclu...

JERSEY CITY, N.J., July 20, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that China’s National Medical Products Administration (NMPA)...

2023-06-21 12:15:22 ET New Jersey-based biotech Scynexis ( NASDAQ: SCYX ) announced Wednesday that it achieved a performance-based milestone payment worth $25M from its partner GSK ( NYSE: GSK ) over its studies into antifungal agent ibrexafungerp. The payment comes afte...